-
公开(公告)号:US20210317468A1
公开(公告)日:2021-10-14
申请号:US17239369
申请日:2021-04-23
Applicant: Arcturus Therapeutics, Inc.
Inventor: Pattraranee Limphong , Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Padmanabh Chivukula , Arisa Cale , Angel I-Jou Leu , Jared Davis
IPC: C12N15/82 , C12N15/52 , C07K14/805 , C07K14/775 , C07K14/75 , C07K14/47 , C07K14/415 , C07K14/505
Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
-
公开(公告)号:US10980895B2
公开(公告)日:2021-04-20
申请号:US16527955
申请日:2019-07-31
Applicant: Arcturus Therapeutics, Inc.
Inventor: Joseph E. Payne , Padmanabh Chivukula , Priya Karmali , Steven P. Tanis
IPC: C07C333/04 , A61K48/00 , A61K9/51 , A61K47/20 , A61P31/00
Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene or alkenylene consisting of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US10815463B2
公开(公告)日:2020-10-27
申请号:US15806096
申请日:2017-11-07
Applicant: Arcturus Therapeutics, Inc.
Inventor: Padmanabh Chivukula , Luigi Warren , Kiyoshi Tachikawa , Joseph E. Payne
IPC: A61K48/00 , C07H21/02 , C07H21/04 , C12N9/10 , C07K14/46 , C07K14/47 , C07K14/505 , C07K14/52 , C07K14/575 , C07K14/705 , C07K14/745 , C07K14/805 , C07K14/81 , C12N9/02 , C12N9/12 , C12N9/44 , C12N9/64 , C12N9/88 , C07K14/445 , A61K39/00
Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.
-
公开(公告)号:US20200297634A1
公开(公告)日:2020-09-24
申请号:US16823212
申请日:2020-03-18
Applicant: Arcturus Therapeutics, Inc.
Inventor: Priya KARMALI , Padmanabh Chivukula , Joseph E. Payne , Yanjie Bao
Abstract: A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.
-
公开(公告)号:US10519447B2
公开(公告)日:2019-12-31
申请号:US15563579
申请日:2016-04-01
Applicant: Arcturus Therapeutics, Inc.
Inventor: Padmanabh Chivukula , Kiyoshi Tachikawa , Joseph E. Payne
IPC: C12N15/113 , A61P9/00 , A61P31/14 , A61P25/00
Abstract: This invention provides UNA oligomers for regulating the expression of a target gene. The UNA oligomers contain UNA monomer linkers, and may contain one or more nucleotides modified with a 2′-O-methyl group, one or more nucleotides modified with a 2′-deoxy-2′-fluoro group, and one or more phosphorothioate or chiral phosphorothioate intermonomer linkages. UNA oligomers can be used as active agents for preventing or treating disease.
-
公开(公告)号:US10421964B2
公开(公告)日:2019-09-24
申请号:US15876127
申请日:2018-01-20
Applicant: Arcturus Therapeutics, Inc.
Inventor: Kiyoshi Tachikawa , Joseph E. Payne , Padmanabh Chivukula
IPC: C12N15/113 , A61K9/127 , A61K31/685 , A61K31/713 , C12N15/11 , A61K9/00
Abstract: This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting expression of a TTR gene in a subject. The compounds have a first strand and a second strand, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of a TTR gene.
-
公开(公告)号:US10369232B2
公开(公告)日:2019-08-06
申请号:US15272107
申请日:2016-09-21
Applicant: Arcturus Therapeutics, Inc.
Inventor: Padmanabh Chivukula , Rachel Wilkie-Grantham , Kiyoshi Tachikawa
IPC: A61K48/00 , C12N15/113 , C12N15/90
Abstract: This invention encompasses compounds, structures, compositions and methods for therapeutic guide molecules that direct CRISPR gene editing. A guide molecule for directing gene editing can be allele selective, or disease allele selective, and can exhibit reduced off target activity. A guide molecule can be composed of monomers, including UNA monomers, nucleic acid monomers, and modified nucleotides, wherein the compound is targeted to a genomic DNA. The guide molecules of this invention can be used as active ingredients for editing or disrupting a gene in vitro, ex vivo, or in vivo.
-
公开(公告)号:US10227302B2
公开(公告)日:2019-03-12
申请号:US15893362
申请日:2018-02-09
Applicant: Arcturus Therapeutics, Inc.
Inventor: Joseph E. Payne , Padmanabh Chivukula , Steven P. Tanis
IPC: C07D211/60 , C07D207/16 , A61K31/713 , A61K47/54 , A61K9/127
Abstract: What is described is a compound wherein R1 and R2 are the same or different, each a linear or branched alkyl consisting of 1 to 20 carbons, or a linear or branched alkenyl or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a bond, a linear alkylene of 1-18 carbons, or a linear alkenylene consisting of 2 to 18 carbons; L3 is a bond or a linear or branched alkylene consisting of 1 to 6 carbons; L4 is a bond or a methylene; X is S or O, R3 is a linear or branched alkylene consisting of 1 to 6 carbons, and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US20190002906A1
公开(公告)日:2019-01-03
申请号:US15994683
申请日:2018-05-31
Applicant: Arcturus Therapeutics, Inc.
Inventor: Pattraranee Limphong , Carlos G. Perez-Garcia , Kiyoshi Tachikawa , Padmanabh Chivukula , Arisa Cale , Angel I-Jou Leu , Jared Davis
IPC: C12N15/82 , C12N15/52 , C07K14/805 , C07K14/775 , C07K14/75 , C07K14/47 , C07K14/415
Abstract: This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.
-
公开(公告)号:US20180362985A1
公开(公告)日:2018-12-20
申请号:US16109231
申请日:2018-08-22
Applicant: Arcturus Therapeutics, Inc.
Inventor: Kiyoshi Tachikawa , Joseph E. Payne , Padmanabh Chivukula
IPC: C12N15/113 , A61K47/14 , A61K31/713
Abstract: This invention provides UNA oligomers for gene silencing with reduced off-target effects. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers and various nucleic acid monomers. Embodiments include pharmaceutical compositions and methods for treating or preventing TTR-related amyloidosis with reduced off-target effects by administering a UNA oligomer to a subject.
-
-
-
-
-
-
-
-
-